Here are four quick facts:
1. One analyst gave the shares a “buy” rating and three gave the shares a “neutral” rating on Feb. 29.
2. No analysts rated the shares a “sell” or “strong sell.”
3. On Jan. 28, Leerink Swann reiterated CONMED’s “outperform” rating.
4. Leerink Swann has a price target of $50 on CONMED shares.
More articles on devices:
InVivo Therapeutics receives Objective Performance Criterion for study: 5 insights
North America dominates global orthopedic prosthetic devices market: 5 things to know
Integra LifeSciences Holdings short interest decreases: 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
